Overexpression of the bcl-2 oncogene in the lymphoid compartment of transgenic mice prolongs the lifespan of lymphocytes and leads to a low incidence of lymphomas at later age. Transgenic mice carrying a mutated T-cell receptor lacking the variable domain (DV-TCRb) suer from lymphocyte depletion and are highly predisposed to lymphoma development. We intercrossed Bcl-2-Ig and DV-TCRb transgenic mice to assess whether Bcl-2 could synergize with DV-TCRb in tumorigenesis as reported previously for other oncogenes. Surprisingly, bitransgenic DV-TCRb; bcl-2-Ig mice showed a reduction in the incidence of lymphomas. Analyses of prelymphomatous mice showed that Bcl-2 restored some of the phenotypic aberrations caused by the DV-TCRb transgene in the lymphoid compartment. The inhibitory activity of Bcl-2 on DVTCRb-induced lymphomagenesis was not observed when both transgenes were crossed into the RAG-1 7/7 background suggesting an important role for more mature lymphocytes in this phenomenon. These results show that, depending on the speci®c conditions, overexpression of Bcl-2 can both promote as well as impair lymphoma development.
Introduction
Overexpression of the bcl-2 oncogene (Tsujimoto et al., 1985; Bakhshi et al., 1985; Cleary et al., 1986) in the lymphoid compartment of transgenic mice induces lymphomas later in life (McDonnell and Korsmeyer, 1991; Strasser et al., 1993) . Bcl-2 collaborates with other oncogenes in lymphomagenesis (Strasser et al., 1990; Acton et al., 1992) , supposedly by prolonging the longevity of preneoplastic lymphocytes (McDonnell et al., 1989 (McDonnell et al., , 1990 Strasser et al., 1991) thereby increasing the chance of accumulation of additional oncogenic events. DV-TCRb transgenic mice are highly predisposed to pre-T-cell lymphomas. The DV-TCRb transgene exerts its oncogenic eect at least at two levels; the DV-TCRb chain arrests T-cell development at the CD4 + 8 + ; CD3 dull stage and DV-TCRb expression also causes depletion of lymphocytes (Krimpenfort et al., 1989) . Depletion of lymphocytes is possibly caused by a direct detrimental eect of DV-TCRb expression during early T-cell development. Support for the combined involvement of both eects in lymphomagenesis came from the observation that introduction of a functional TCRb transgene abolishes the differentiation arrest induced by the DV-TCRb transgene and drastically reduces lymphomagenesis while lymphocyte depletion is still evident in these bitransgenic mice (Jacobs et al., 1996) . In addition, in a transgenic line in which the DV-TCRb transgene is integrated in the Xchromosome, female mice do not show lymphocyte depletion and do not develop lymphomas. This is most probably due to the presence of lymphocytes with an X-chromosomally inactivated transgene, since male mice and female mice homozygous for the transgene do develop lymphomas (Jacobs et al., 1996) . Apparently, both the dierentiation arrest and lymphocyte depletion are contributing to the high lymphoma incidence in these mice. In order to study whether Bcl-2 could synergize with DV-TCRb in lymphomagenesis, as reported previously for Bcl-2 and other oncogenes (Strasser et al., 1990; Acton et al., 1992) , we intercrossed bcl-2 and DV-TCRb transgenic mice. Here we report on the unexpected ®nding that Bcl-2 reduces DV-TCRb induced lymphomagenesis.
Results and discussion
To assess the eect of Bcl-2 on DV-TCRb-induced lymphomagenesis we intercrossed DV-TCRb (line 1735, which has an X-linked transgene; Jacobs et al., 1996) homozygous females and bcl-2-Ig (line 43; McDonnell et al., 1989) heterozygous males. From a set of 11 crosses done at the same time 87 ospring were obtained. As expected, tail DNA analyses revealed that all 87 ospring carried the DV-TCRb transgene. Of these 38 were also positive for the bcl-2-Ig transgene. The male : female ratio observed was 52 : 35. From this population 84 mice were monitored for lymphoma development. The survival curves of the resulting four dierent F1 populations and the number of animals in each group are depicted in Figure 1 . Male DV-TCRb mice developed lymphomas at high frequency. The ®rst lymphomas appeared after 14 weeks, and 50% of the animals had succumbed at 29 weeks of age. At this time only 21% of the DV-TCRb; bcl-2-Ig bitransgenic males had developed lymphomas. The onset of lymphomagenesis in this group started after 27 weeks. After 1 year 85% of the DV-TCRb males had developed lymphomas compared to only 44% of the bitransgenic males. All female ospring remained lymphoma free in this period. No dierences were observed in the phenotype of lymphomas from DV-TCRb; bcl-2-Ig or DV-TCRb transgenic mice (Jacobs et al., 1996) (Jacbos et al., 1996) . In these tumors both transgenes were expressed as determined by Northern blot analysis (not shown).
To study the early eects of bcl-2 overexpression in DV-TCRb transgenic mice we compared prelymphomatous male littermates (4 ± 12 weeks old) for phenotypic changes in the lymphoid compartment. Male DV-TCRb transgenic mice suer from a T-cell depletion leading to a reduction in the number of thymocytes to about 10 ± 30% of wild-type levels. In addition, T-cell dierentiation is arrested at the CD4 + ;CD8 + ;CD3 dull stage although a small percentage of the thymocytes do mature to single positive T cells with high CD3 expression (Krimpenfort et al., 1989; Figure 2a and b) . In bcl-2-Ig transgenic mice the surface phenotype of the thymus is not aected (McDonnell et al., 1989 (McDonnell et al., , 1990 ) although the transgene is functionally expressed (Brady et al., 1996a) . In bitransgenic males the same was observed as seen in DV-TCRb males. Thymocyte depletion was still evident and no signi®cant dierence was found in the percentage of CD3-bright thymocytes, indicating that bcl-2 had no discernible impact on the DV-TCRb induced depletion and block in thymocyte differentiation (Krimpenfort et al., 1989) .
In DV-TCRb transgenic males the total number of splenocytes was slightly reduced with 30% compared to control littermates but a signi®cant reduction of total splenic T cells was observed in DV-TCRb transgenic males (Krimpenfort et al., 1989 Figure 3a and b). Interestingly overexpression of bcl-2 restored the DV-TCRb chain induced reduction of peripheral T cell numbers to wild type levels (Figure 3b ). Consistent with previous data an expansion of the B-cell compartment was observed in mice overexpressing bcl-2 (McDonnell et al., 1989; Figure 3c ).
To estimate the eects of the transgenes on splenocyte viability we compared the in vitro survival of splenocytes in the absence of growth factors. DVTCRb splenocytes are short-lived as compared to wild-type cells. However, introduction of bcl-2 increased survival of the DV-TCRb cells to the level observed in wild type splenocytes (Figure 3d ). The increased survival was not only attributable to the Bcell population of the spleen (McDonnell et al., 1989) because a similar eect of Bcl-2 was also observed for B-cell depleted splenocytes (Figure 3e ). To determine whether Bcl-2 aected other characteristics of these cells, mitogen induced proliferative responses of Tand B-splenocytes were measured. Thymidine incorporation upon concavalin-A (ConA) or anti-CD3 (not shown) stimulation for T cells and upon LPS stimulation for B cells showed a dierence in the eects of Bcl-2 on DV-TCRb T and B cells (Figure 3f and g). In DV-TCRb transgenic males the T cell and B cell responses were signi®cantly reduced. The bcl-2-Ig T cells and B cells showed an increased response compared to control littermates. In bitransgenic males T-cell responses to ConA or anti-CD3 were still impaired whereas the B-cell response to LPS was restored to wild-type levels. Figure 1 Bcl-2 overexpression reduces DV-TCRb induced lymphoma incidence. Lymphoma incidence in ospring from crosses between homozygous DV-TCRb female mice (Xchromosomal founderline 1735) and heterozygous bcl-2-Ig males (founderline 43). The F1 population was monitored for lymphoma development for a period of 1 year. Mice were sacri®ced when lymphoma development was diagnosed. The number of animals monitored in each group is indicated (n) The eects of Bcl-2 on the DV-TCRb transgene phenotype were not restricted to the splenocytes. The DV-TCRb transgene is also expressed in the bone marrow compartment. When bone marrow was assayed for the number of colony forming cells in response to IL-7, a dramatic reduction was observed in DV-TCRb males that could be restored by Bcl-2 (Figure 4a ). Similar eects of the transgenes were seen on the response to IL-7+SF (Steel Factor) (Figure 4b ). IL-7 stimulates pre-B cells (Lee et al., 1989) whereas the combination of IL-7 and SF also recruits progenitor B cells (McNiece et al., 1991) , indicating that Bcl-2 can mitigate the detrimental eects of DV-TCRb expression on B-cell precursors as well. The number of myeloid cells responding to M-CSF is not aected by the transgenes (Figure 4c) .
The absence of a signi®cant eect of Bcl-2 on the thymus phenotype induced by DV-TCRb with the concomitant major eect on splenic lymphocytes suggests the possible involvement of mature lymphocytes in the lymphoma suppressive eect. If mature lymphocytes play such a role one would predict this lymphoma suppressive eect to be absent in compound mutant mice that cannot produce mature lymphocytes. Therefore, we determined the incidence of lymphomas in DV-TCRb and DV-TCRb; bcl-2-Ig males in the 
RAG-1
7/7 background. RAG-1 7/7 mice lack mature lymphocytes due to inactivation of the recombination machinery (Mombaerts et al., 1992) . In the absence of lymphocyte maturation, DV-TCRb transgenic mice still develop lymphomas at the same rate as observed in a wild-type background. The surface phenotype of these lymphomas is the same as in the wild-type background (Jacobs et al., 1996 ; Figure 5 and Figure 1) . Interestingly, bcl-2 has no eect on the DV-TCRb induced lymphomagenesis in the RAG-1 7/7 background ( Figure 5 ).
In conclusion, the data presented here demonstrate a remarkable capacity of the Bcl-2 oncogene to reduce the lymphoma incidence in DV-TCRb transgenic mice. Gene transfer mediated overexpression of bcl-2 was reported to inhibit cell growth of several solid tumour cell lines (Pietenpol et al., 1994) and an inverse correlation between bcl-2 expression level and cell proliferation rate was also observed in a panel of lymphoma/leukaemia cell lines (Smets et al., 1994) . Furthermore, recently it was demonstrated that Bcl-2 can inhibit cell cycle progression directly (Brady et al., 1996b; Mazel et al., 1996; Linette et al., 1996; O'Reilly et al., 1996; Vairo et al., 1996) . These eects of Bcl-2 on the cell cycle are separable from the eects on cell survival and seem to be potentiated only in response to environmental cues. This raises the possibility that Bcl-2 can also impair lymphomagenesis under certain conditions. Bcl-2 overexpression in DV-TCRb transgenic mice could appear to create such conditions. However, the lack of Bcl-2 mediated tumor suppression in the RAG-1 7/7 mice may also point to a systemic eect of Bcl-2 and suggests a role of the mature lymphoid compartment in preventing lymphomagenesis. We can hypothesise that restoring the number and survival of the peripheral lymphocytes by Bcl-2 in some way feeds back on the progenitor compartment, e.g. by reducing the number of cell divisions, leading to a reduced accumulation of oncogenic mutations in precursor lymphocytes and consequently to a decreased lymphoma incidence. A detailed analysis of the size, cycling status and turnover rates and the eects of the DV-TCRb and bcl-2-Ig transgene and the RAG-1 7/7 mutation on these parameters in the speci®c lymphoid subsets will be required to fully understand the critical events that lead to DV-TCRb induced lymphoma development and to determine if the lymphoma inhibitory eect of Bcl-2 is caused by direct or indirect mechanisms.
Materials and methods

Transgenic mice
The derivation of the DV-TCRb transgenic mouse strain was described (Krimpenfort et al., 1989) . In this study we used founderline 1735 generated in CBA/BRxC57BL/LiA and backcrossed with C57BL/LiA mice. In founderline 1735 the transgene is integrated on the X-chromosome (Jacobs et al., 1996) . Bcl-2-Ig transgenic mice (McDonnell et al., 1989) founderline 43 (generously provided by S Korsmeyer) were generated in the C3H-57BL/6 and backcrossed with C57BL/ 6. Homozygous female DV-TCRb transgenic mice were crossed with (heterozygous) male bcl-2-Ig transgenic mice to obtain four dierent F1 populations. A total population of 87 animals was obtained. All animals were tail analysed for the presence of the transgenes. As expected all 87 mice were DV-TCRb transgenics. Of these 38 mice also carried the bcl-2-Ig transgene of which 20 were females and 18 were males. Of this population 84 mice were monitored for lymphoma development for 1 year. RAG-1 7/7 mice (Mombaerts et al., 1992) (kindly provided by S Tonegawa) generated and bred in the OLA/129 strain were ®rst crossed twice with DVTCRb or bcl-2-Ig transgenic mice to obtain female DVTCRb; RAG-1 7/7 mice and male bcl-2-Ig; RAG-1 7/7 mice, which were subsequently intercrossed. The male ospring was monitored for lymphoma development for 36 weeks.
Lymphoma pathology
For lymphoma incidence mice were monitored weekly and sacri®ced when lymphoma development was diagnosed. background. Female DV-TCRb; RAG-1 7/7 mice and male bcl-2-Ig; RAG-1 7/7 mice were intercrossed. Male ospring were monitored for lymphoma development for 36 weeks 
FACS analysis
Flow cytometric analysis of cell surface markers expressed by the lymphoma cells or lymphocytes was performed as described (Jacobs et al., 1996) , using antibodies against CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6,7), TCRab (H57-597) and B220 (RA3-6B2) (Pharmingen, San Diego, CA), on a FACScan (Becton Dickinson, Mountain View, CA). B-cell depletion was accomplished using monoclonal antibodies against B220 coupled to magnetic beads. Lymphocyte counts were performed in a Sysmex Toa F800 microcellcounter (Kobe, Japan).
In vitro cell survival and growth factor response assays
Total cell suspensions from spleens were washed, counted and seeded at a concentration of 5610 6 /ml in RPMI1640+5% FCS. B-cell depleted suspensions were seeded at 2610 6 in Iscove+5% FCS. Viable cell concentrations were determined by trypan blue exclusion counts using an improved Neubauer haemocytometer. LPS response on total splenocytes and ConA and anti-CD3 response for B-cell depleted splenocytes were performed as described (Carrozza et al., in press ). Colony assays on unfractionated bone marrow was performed by plating 5610 4 bone marrow cells in 1 ml medium containing 0.25% agar and growth factor in 3.5 cm dishes exactly as described (Domen et al., 1993) .
